Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.44 |
| ▸ | GABRP | O00591 | 6/20 | 0.44 |
| ▸ | GABRD | O14764 | 6/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.44 |
| ▸ | GABRE | P78334 | 6/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537795 | 1.00 | ALDH1A1 (0.48) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL16094787 | 0.91 | ALDH1A1 (0.48) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL29537205 | 0.89 | GAA (0.59) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL20944365 | 0.89 | GAA (0.59) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL8536749 | 0.88 | CYP1A2 (0.49) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL29537157 | 0.86 | CYP1A2 (0.47) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL16094911 | 0.86 | CYP1A2 (0.47) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL29272497 | 0.84 | GABRA1 (0.44) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL29272298 | 0.83 | AR (0.49) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 | |
| SCHEMBL29272345 | 0.82 | GABRA1 (0.42) | ALDH1A1GAAL3MBTL1CYP1A2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-105143209-A | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG | 2015-12-09 | — | — | CN | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-8802850-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ALDH1A1 1859/4885GAA 3482/4885L3MBTL1 2805/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ALDH1A1 1592/4885GAA 1032/4885L3MBTL1 2970/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 1592/4885GAA 1032/4885L3MBTL1 2970/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALDH1A1 1592/4885GAA 1032/4885L3MBTL1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.